![](https://investorshub.advfn.com/uicon/339818.png?cb=1566501296)
Monday, June 17, 2024 9:18:27 AM
Ec
my post are not for investment purposes..do not invest or trade on anything i post
Recent MBIO News
- Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy • GlobeNewswire Inc. • 06/17/2024 12:30:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/13/2024 04:15:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:00:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 12:35:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 12:33:33 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/31/2024 09:09:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:15:26 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/13/2024 10:01:30 AM
- Mustang Bio Announces Closing of $4 Million Public Offering • GlobeNewswire Inc. • 05/02/2024 08:01:07 PM
- Mustang Bio Announces Pricing of $4 Million Public Offering • GlobeNewswire Inc. • 04/30/2024 12:00:07 AM
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases • GlobeNewswire Inc. • 03/28/2024 01:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:30:31 PM
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/11/2024 08:05:12 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 08:02:09 PM
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma • GlobeNewswire Inc. • 03/07/2024 12:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:07:36 PM
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/11/2024 01:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:05:12 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:06:38 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/12/2023 02:52:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:37:55 PM
- Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting • GlobeNewswire Inc. • 12/11/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:44:14 PM
- Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/14/2023 09:05:43 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM